Adagio Therapeutics
26 articles with Adagio Therapeutics
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Although it looks that we’re on the downside of the COVID-19 pandemic in the U.S., biopharma companies are still working on developing better treatments and preventions.
-
Adagio Therapeutics has appointed current COO David Hering as interim CEO, replacing Tillman Gerngross, Ph.D., who communicated his intention to resign in mid-February.
-
Weeks after announcing that its lead monoclonal antibody was demonstrating efficacy against the Omicron variant, Adagio Therapeutics CEO Tillman Gerngross steps down.
-
Amagma Therapeutics announced a licensing agreement with Innovent Biologics for up to three enzyme specific inhibitors derived from Amagma’s proprietary SEIZMIC Platform.
-
Adagio cited three recent independent, in vitro studies showing that ADG20, which is currently undergoing Phase II/III clinical trials, has neutralization activity against Omicron.
-
23andMe, EQRx Lead IPO Rush in 2021
12/21/2021
The year kicked off with a bang as multiple companies raced to a public listing. -
Omega raised $650 million, which it plans to invest in life science companies in the U.S. and Europe.
-
Adagio claims that none of the mutations found in Omicron are linked with escape from ADG20 neutralization in vitro.
-
Adagio Therapeutics Announces Pricing of Initial Public Offering
8/6/2021
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced the pricing of its initial public offering of 18,200,000 shares of common stock at a price to the public of $17.00 per share.
-
Show me the money! This week's who's who of IPOs and financing rounds in the biopharma world.
-
It is offering 17.7 million shares with an expected price between $16 and $18 per share. It will trade on the Nasdaq under the ADGI ticker symbol.
-
Adagio Therapeutics Appoints Leading Pharmaceutical and Regulatory Executives to its Board of Directors
7/29/2021
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, announced the expansion of the company’s board of directors with key appointments, including:
-
Adagio Therapeutics Partners with Biocon Biologics to Bring Potent and Broadly Neutralizing COVID-19 Antibody Treatment to Patients in India and Select Emerging Markets
7/26/2021
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced a partnership agreement with Biocon Biologics Ltd., to combat the ongoing COVID-19 crisis in southern Asia.
-
Adagio Therapeutics Appoints David Hering, Global COVID-19 Vaccine Expert, as Chief Operating Officer
7/19/2021
Adagio Therapeutics, Inc., a biotechnology company developing highly differentiated antibodies to broadly neutralize coronaviruses, announced that David Hering has been appointed as the company’s chief operating officer.
-
Skylight Health Announces Award of US Clinical Trial
6/2/2021
Skylight Health has been selected as a clinical site to enroll patients for a clinical research trial investigating ADG20, a broadly neutralizing monoclonal antibody, for use in the prevention of COVID-19
-
Adagio Therapeutics Announces ADG20 Phase 1 Data and Initiation of Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19
5/5/2021
Adagio Therapeutics, Inc., a biotechnology company developing highly differentiated antibodies to broadly neutralize coronaviruses, today announced that the first patient has been treated in the company’s Phase 2/3 pivotal trial evaluating ADG20 for the prevention of COVID-19, known as the EVADE trial.
-
BioSpace takes a look at data released this week from some of the numerous ongoing clinical studies to advance potential therapies and treatment for disease. Here are some of them.
-
Money on the Move: April 14-20
4/21/2021
Investment funds continue springing up into life sciences companies across the globe. Here’s where the money’s being planted this week.